Evidence map›Paper›PMID 37450086›Full record

Trial reportJournal of patient-reported outcomes2023

Validation of NASH-CHECK: a novel patient-reported outcome measure for nonalcoholic steatohepatitis.

James Twiss, Diane Whalley, Lynda Doward, Maria-Magdalena Balp, Clifford A Brass, Donna Cryer, Arun Sanyal, Quentin M Anstee

2 registry-linked trialsAbstract readRandomized Controlled TrialClinical Trial, Phase II
In one paragraph

Trial report in Journal of patient-reported outcomes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02855164 phase2terminatednot on this map

A Randomized, Double-blind, Placebo Controlled, 3- Part, Adaptive Design, Multicenter Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH): FLIGHT-FXR

TypeinterventionalSponsorNovartis PharmaceuticalsRan2016 to 2020Enrolled350ConditionsNon-alcoholic Steatohepatitis (NASH)ArmsTropifexor (LJN452), Placebo
NCT07493967 enrolling by invitationnot on this mapstarted 2024, after this paper: background citation

Short and Long Term Clinical and Patient-Reported Outcomes Associated With Intragastric Balloon Placement in Patients With Nonalcoholic Fatty Liver Disease

TypeobservationalSponsorMethodist Health SystemRan2024 to 2027Enrolled200ConditionsNAFLD
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. The Role of Patient-Reported Outcomes in Cirrhosis.The American journal of gastroenterology · 2025
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

James TwissRTI Health Solutions, Manchester, M20 2LS, UK. jtwiss@rti.org.
Diane WhalleyRTI Health Solutions, Manchester, M20 2LS, UK.
Lynda DowardRTI Health Solutions, Manchester, M20 2LS, UK.
Maria-Magdalena BalpNovartis Pharma AG, Basel, Switzerland.
Clifford A BrassNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Donna CryerGlobal Liver Institute, Washington, DC, USA.
Arun Sanyal *Virginia Commonwealth University, Richmond, VA, USA.
Quentin M Anstee *Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStandardized measures for evaluating patients' experiences with nonalcoholic steatohepatitis (NASH) and their perceived changes with treatment in clinical trials have been limited. To meet this need, a patient-reported outcome (PRO) measure, NASH-CHECK, was developed to evaluate symptoms and health-related quality of life for patients with NASH. The objective of this study was to conduct a quantitative evaluation of the psychometric properties of NASH-CHECK.

methodsThe study used data from a phase 2, randomized controlled trial of adult patients with NASH (NCT02855164). Analyses were conducted to determine the optimal scoring of NASH-CHECK and to evaluate reliability, construct validity, and ability to detect change in NASH-CHECK scale scores.

resultsData were available for 253 patients with NASH (61% female; mean [standard deviation] age = 53 [12] years). Following initial item-level analyses, including correlations and exploratory factor analysis, three items were removed from the measure. Confirmatory factor analysis supported the formation of four multi-item scales (Cognitive Symptoms, Activity Limitations, Social Impact, and Emotional Impact) and five single-item scales (Abdominal Pain, Abdominal Bloating, Fatigue, Sleep, and Itchy Skin). Psychometric analyses of the final NASH-CHECK scales provided support for their internal reliability, test-retest reliability, construct validity, and ability to detect change.

conclusionThe results support NASH-CHECK as a reliable, valid, and responsive measure to assess patients' perspectives of symptoms and the health-related quality of life impact of NASH in clinical trials and in routine practice.

Indexed as

Non-alcoholic Fatty Liver DiseaseQuality of LifeAdultFemaleHumansMaleMiddle AgedPatient Reported Outcome MeasuresReproducibility of ResultsSurveys and QuestionnairesHealth-related quality of life (HRQOL)ReliabilityResponsivenessSymptomsValidity

Identifiers

PMID37450086
PMCPMC10349018

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.